Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
出版年份 2012 全文链接
标题
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
作者
关键词
-
出版物
LIVER TRANSPLANTATION
Volume 18, Issue 9, Pages 1053-1059
出版商
Wiley
发表日期
2012-06-18
DOI
10.1002/lt.23482
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon
- (2012) Josh Levitsky et al. GASTROENTEROLOGY
- 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
- (2012) F. Suzuki et al. JOURNAL OF HEPATOLOGY
- 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
- (2012) M. Sulkowski et al. JOURNAL OF HEPATOLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin
- (2011) Jee Eun Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men
- (2011) Jennifer C. Lai et al. HEPATOLOGY
- Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus
- (2011) Varun Garg et al. HEPATOLOGY
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation
- (2010) P. Guillouche et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab
- (2010) Maria L Alcaide et al. CLINICAL TRANSPLANTATION
- Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients
- (2010) Nazia Selzner et al. JOURNAL OF HEPATOLOGY
- Post-liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteria
- (2010) Tarun K. Narang et al. LIVER TRANSPLANTATION
- Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection
- (2008) B. J. Veldt et al. AMERICAN JOURNAL OF TRANSPLANTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started